Table 3 DA-EPOCH-B overall response and... | American Society of Hematology

Table 3

DA-EPOCH-B overall response and by molecular subtype

Treatment group	n (%)	Response, n (%)			P*
Treatment group	n (%)	Complete	Partial	None	P*
All patients	44	8 (18)	7 (16)	29 (66)
DLBCL (de novo)†	31 (70)	7 (23)	6 (19)	18 (58)	.63
Molecular subtypes‡	27	6 (22)	6 (22)	15 (56)
ABC DLBCL	12 (44)	5 (41.5)	5 (41.5)	2 (17)
GCB DLBCL	15 (56)	1 (6.5)	1 (6.5)	13 (87)	< .001

Treatment group	n (%)	Response, n (%)			P*
Treatment group	n (%)	Complete	Partial	None	P*
All patients	44	8 (18)	7 (16)	29 (66)
DLBCL (de novo)†	31 (70)	7 (23)	6 (19)	18 (58)	.63
Molecular subtypes‡	27	6 (22)	6 (22)	15 (56)
ABC DLBCL	12 (44)	5 (41.5)	5 (41.5)	2 (17)
GCB DLBCL	15 (56)	1 (6.5)	1 (6.5)	13 (87)	< .001

Fisher exact test.

Excluding primary mediastinal B-cell lymphomas (PMBL).

All de novo DLBCL except PMBL with microarray or immunohistochemical determination of molecular subtype.